Preclinical evaluation of a novel and orally active proteasome inhibitor as a therapy in relapsed/refractory multiple myeloma

被引：0
|
作者：
Chauhan, D
Catley, L
Li, G
Hideshima, T
Richardson, P
Palladino, M
Anderson, KC
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Nereus Pharmaceut, San Diego, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：222S / 222S
页数：1
相关论文
共 50 条
  • [1] Preclinical evaluation of tropolone and proteasome inhibitor therapy for multiple myeloma
    Holstein, Sarah
    Haney, Staci
    Varney, Michelle
    Smith, Lynette
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E130 - E131
  • [2] Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
    Jayaweera, Shansa Pranami E.
    Wanigasinghe Kanakanamge, Sacheela Prasadi
    Rajalingam, Dharshika
    Silva, Gayathri N.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [3] A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma
    Chauhan, Dharminder
    Singh, Ajita V.
    Aujay, Monette
    Kirk, Christopher J.
    Bandi, Madhavi
    Ciccarelli, Bryan
    Raje, Noopur
    Richardson, Paul
    Anderson, Kenneth C.
    BLOOD, 2010, 116 (23) : 4906 - 4915
  • [4] Therapy of relapsed and relapsed refractory multiple myeloma
    Driessen, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 113 - 113
  • [5] Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma
    Leleu, Xavier
    Martin, Thomas G.
    Einsele, Hermann
    Lyons, Roger M.
    Durie, Brian G. M.
    Iskander, Karim S.
    Ailawadhi, Sikander
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (01): : 9 - 22
  • [6] Carfilzomib: A Second-Generation Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
    Thompson, Jennifer L.
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (01) : 56 - 62
  • [7] Phase I Study of a Novel Oral Proteasome Inhibitor TQB3602 in Relapsed/Refractory Multiple Myeloma
    Tang, Wenjiao
    Li, Yan
    Liang, Qiushi
    Qu, Ying
    Zhang, Li
    Liu, Yuzhang
    Fang, Baijun
    Yun, Zeng
    Du, Xiaobo
    Xi, Yaming
    Wang, Ting
    Li, Xin
    Huang, Jie
    Qian, Wenbin
    Cai, Zhen
    Zhao, Qingwei
    Lv, Yue
    Niu, Ting
    BLOOD, 2022, 140 : 4396 - 4397
  • [8] Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects
    Vij, Ravi
    Wang, Luhua
    Orlowski, Robert Z.
    Stewart, A. Keith
    Jagannath, Sundar
    Lonial, Sagar
    Trudel, Suzanne
    Jakubowiak, Andrzej J.
    Belch, Andrew
    Alsina, Melissa
    Bahlis, Nizar J.
    Le, Mai H.
    Cruickshank, Scott
    Bennett, Mark K.
    Molineaux, Susan
    Kauffman, Michael
    Siegel, David
    BLOOD, 2009, 114 (22) : 178 - 179
  • [9] New orally active proteasome inhibitors in multiple myeloma
    Allegra, Alessandro
    Alonci, Andrea
    Gerace, Demetrio
    Russo, Sabina
    Innao, Vanessa
    Calabro, Laura
    Musolino, Caterina
    LEUKEMIA RESEARCH, 2014, 38 (01) : 1 - 9
  • [10] A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
    Chauhan, D
    Catley, L
    Li, GL
    Podar, K
    Hideshima, T
    Velankar, M
    Mitsiades, C
    Mitsiades, N
    Yasui, H
    Letai, A
    Ovaa, H
    Berkers, C
    Nicholson, B
    Chao, TH
    Neuteboom, STC
    Richardson, P
    Palladino, MA
    Anderson, KC
    CANCER CELL, 2005, 8 (05) : 407 - 419
12345